MedTrace Logo

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

NCT05136456 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2023-09-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.

Conditions

Interventions

DRUG

SHR1459 Low Dose

SHR1459 oral tablets taken once daily (QD) for 24weeks

DRUG

SHR1459 High Dose

SHR1459 oral tablets taken once daily (QD) for 24 weeks

DRUG

Placebo

Placebo oral tablets taken once daily (QD) for 24 weeks

Sponsors & Collaborators

  • Reistone Biopharma Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2023-08-28
Completion
2024-03-11

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05136456 on ClinicalTrials.gov